{"id":11422,"date":"2017-04-06T17:14:27","date_gmt":"2017-04-06T15:14:27","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2021\/oncgnostics-grants-gyntect-licence-to-sinopharm-subsidiary-cjmt\/"},"modified":"2021-01-28T13:09:54","modified_gmt":"2021-01-28T12:09:54","slug":"oncgnostics-grants-gyntect-licence-to-sinopharm-subsidiary-cjmt","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2017-en\/oncgnostics-grants-gyntect-licence-to-sinopharm-subsidiary-cjmt\/","title":{"rendered":"oncgnostics grants GynTect licence to SINOPHARM subsidiary CJMT"},"content":{"rendered":"

The Chi\u00adnese phar\u00adma\u00adceu\u00adti\u00adcal com\u00adpany Changchun Jienuo Med\u00adical Tech\u00adnol\u00adogy (CJMT), a sub\u00adsidiary of the Chi\u00adnese state-owned Sinopharm Group (www.sinopharm.com\/en<\/a>), has acquired an exclu\u00adsive licence for the cer\u00advi\u00adcal can\u00adcer screen\u00ading test Gyn\u00adTect for China, Hong Kong and Macao from the Jena-based com\u00adpany oncg\u00adnos\u00adtics (www.oncgnostics.com<\/a>). A four-mile\u00adstone agree\u00adment out\u00adlines how to obtain China Food and Drug Admin\u00adis\u00adtra\u00adtion (CFDA) approval for Gyn\u00adTect within three years. oncg\u00adnos\u00adtics will receive upfront and mile\u00adstone pay\u00adments as well as a share of future sales.<\/strong>
\nThe offi\u00adcial sign\u00ading of the con\u00adtract took place dur\u00ading a visit of the Chi\u00adnese part\u00adner in the sci\u00adence city of Jena in the pres\u00adence of the man\u00adag\u00ading direc\u00adtor of the Sinopharm Group Jianxin Guo and the Thuringian Min\u00adis\u00adter of Eco\u00adnom\u00adics and Sci\u00adence Wolf\u00adgang Tiefensee. \u201concg\u00adnos\u00adtics GmbH is an excel\u00adlent exam\u00adple of how research in Jena can form the basis for a promis\u00ading busi\u00adness model. The coop\u00ader\u00ada\u00adtion with the Chi\u00adnese part\u00adner on the dis\u00adtri\u00adb\u00adu\u00adtion of the clar\u00adi\u00adfi\u00adca\u00adtion test Gyn\u00adTect\u00ae is the right and impor\u00adtant step towards inter\u00adna\u00adtion\u00adal\u00adis\u00ading the com\u00adpany and open\u00ading up the world\u2019s largest mar\u00adket of female patients. This shows that the pro\u00admo\u00adtion of sub\u00adstan\u00adtial inno\u00adv\u00ada\u00adtive start-ups, which is a spe\u00adcial focus of our eco\u00adnomic pol\u00adicy, pays off,\u201d explained Wolf\u00adgang Tiefensee on the occa\u00adsion of the sign\u00ading of the contract.
\nThe mol\u00ade\u00adc\u00adu\u00adlar bio\u00adlog\u00adi\u00adcal test Gyn\u00adTect devel\u00adoped by oncg\u00adnos\u00adtics deter\u00admines at an early stage whether a patient with a con\u00adspic\u00adu\u00adous Pap test result or a human papil\u00adlo\u00admavirus infec\u00adtion (HPV) has a cer\u00advi\u00adcal car\u00adci\u00adnoma (cer\u00advi\u00adcal can\u00adcer) that needs to be treated. Gyn\u00adTect pro\u00advides fast and reli\u00adable exam\u00adi\u00adna\u00adtion results and thus gives affected women just as much cer\u00adtainty as to how best to pro\u00adceed with a con\u00adspic\u00adu\u00adous pre\u00adlim\u00adi\u00adnary exam\u00adi\u00adna\u00adtion. This greatly facil\u00adi\u00adtates risk assess\u00adment in early cer\u00advi\u00adcal can\u00adcer detec\u00adtion: on the one hand, unnec\u00ades\u00adsary, pre\u00adma\u00adture oper\u00ada\u00adtions can be avoided, and on the other hand, the chances of suc\u00adcess\u00adful treat\u00adment mea\u00adsures can be increased.
\nGyn\u00adTect is already approved for use in lab\u00ado\u00adra\u00adto\u00adries through\u00adout Europe via the CE-IVD approval obtained in 2015. The val\u00adi\u00adda\u00adtion of the mark\u00aders, the devel\u00adop\u00adment of the test for\u00admat and the CE-IVD approval of Gyn\u00adTect was dri\u00adven for\u00adward by oncg\u00adnos\u00adtics in close coop\u00ader\u00ada\u00adtion with the Uni\u00adver\u00adsity Wom\u00aden\u2019s Hos\u00adpi\u00adtal Jena on the basis of more than 2000 clin\u00adi\u00adcally val\u00adi\u00addated sam\u00adples. With its part\u00adner CJMT, oncg\u00adnos\u00adtics aims to tap into the huge mar\u00adket in China with an annual mar\u00adket poten\u00adtial of >\u20ac1 billion.
\nThere are over 550 mil\u00adlion women aged 15 and over liv\u00ading in the Peo\u00adple\u2019s Repub\u00adlic of China, all of whom are at risk of devel\u00adop\u00ading cer\u00advi\u00adcal can\u00adcer. \u201cThere is a very high demand for reli\u00adable screen\u00ading and detec\u00adtion tests in China. Gyn\u00adTect will help us to reli\u00adably diag\u00adnose cer\u00advi\u00adcal can\u00adcer and its pre\u00adcur\u00adsors, avoid unnec\u00ades\u00adsary surgery and, most impor\u00adtantly, detect malig\u00adnant tis\u00adsue changes in time,\u201d said Dr Xiaokai Xia, Man\u00adag\u00ading Direc\u00adtor of Chi\u00adnese part\u00adner CJMT at the sign\u00ading ceremony.
\nCJMT is the sub\u00adsidiary of the China National Biotech Group (CNBG) spe\u00adcial\u00adis\u00ading in clin\u00adi\u00adcal diag\u00adnos\u00adtics. Both belong to the state-owned phar\u00adma\u00adceu\u00adti\u00adcal group SINOPHARM (www.sinopharm.com\/en<\/a>). The Sinopharm Group is one of the world\u2019s largest phar\u00adma\u00adceu\u00adti\u00adcal com\u00adpa\u00adnies with over 100,000 employ\u00adees and more than US$40 bil\u00adlion in sales (2015).
\nThe sign\u00ading of the exclu\u00adsive licence agree\u00adment took place on 5 April 2017 at the Bioin\u00adstru\u00adment Cen\u00adtre in Jena in a high-pro\u00adfile gath\u00ader\u00ading. Eco\u00adnom\u00adics Min\u00adis\u00adter Wolf\u00adgang Tiefensee wel\u00adcomed the 11-mem\u00adber Chi\u00adnese del\u00ade\u00adga\u00adtion. With Jianxin Guo, Man\u00adag\u00ading Direc\u00adtor of Sinopharm Group, Shengyi Shi, Vice Pres\u00adi\u00addent of Sinopharm Group and Xiaom\u00ading Yang, Man\u00adag\u00ading Direc\u00adtor of CNBG, the top man\u00adage\u00adment of Sinopharm was in Jena. In addi\u00adtion to the found\u00ading and man\u00adage\u00adment team of oncg\u00adnos\u00adtics GmbH, Dr. Michael Brand\u00adkamp (High Tech Gr\u00fcn\u00adder Fonds, HTGF) and Udo Werner (Beteili\u00adgungs\u00adman\u00adage\u00adment Th\u00fcrin\u00adgen GmbH, bm\u2011t), the man\u00adag\u00ading direc\u00adtors of the lead investors of oncg\u00adnos\u00adtics\u2019 first two financ\u00ading rounds were also present.<\/p>\n

About GynTect<\/h4>\n

In Ger\u00admany, almost 5,000 new cases of cer\u00advi\u00adcal can\u00adcer are diag\u00adnosed every year and more than 1,600 women die from this dis\u00adease every year. On the other hand, about 200,000 women in Ger\u00admany receive an abnor\u00admal diag\u00adno\u00adsis in the Pap test every year. Only very few of these women have a dis\u00adease that needs to be treated, because most dys\u00adplasias (cell changes) regress on their own. The early detec\u00adtion test Gyn\u00adTect quickly and reli\u00adably pro\u00advides cer\u00adtainty in the case of a pos\u00adi\u00adtive Pap or HPV test result. Gyn\u00adTect can be per\u00adformed on a sam\u00adple that has already been taken for thin-layer cytol\u00adogy. The sen\u00adsi\u00adtiv\u00adity of Gyn\u00adTect for detect\u00ading can\u00adcer is 100%. This means that all patients with cer\u00advi\u00adcal can\u00adcer also received a pos\u00adi\u00adtive result. The test works with bio\u00admark\u00aders that only occur in cer\u00advi\u00adcal can\u00adcer or those dys\u00adplasias that also lead to it.<\/p>\n

About oncgnostics GmbH:<\/h4>\n

oncg\u00adnos\u00adtics GmbH was founded in 2012 as a spin-off from a uni\u00adver\u00adsity research group at the Uni\u00adver\u00adsity Wom\u00aden\u2019s Hos\u00adpi\u00adtal in Jena. As a mol\u00ade\u00adc\u00adu\u00adlar diag\u00adnos\u00adtics com\u00adpany, the Jena-based start-up spe\u00adcialises in the diag\u00adno\u00adsis of can\u00adcer. The tests detect char\u00adac\u00adter\u00adis\u00adtic epi\u00adge\u00adnetic changes, so-called DNA methy\u00adla\u00adtions, in can\u00adcer cells. The bio\u00admark\u00aders iden\u00adti\u00adfied and patented with a spe\u00adcial algo\u00adrithm form the core of the prod\u00aducts and are the basis of the company.<\/p>\n

About SINOPHARM Group and CJMT:<\/h3>\n

China National Phar\u00adma\u00adceu\u00adti\u00adcal Group Corp. (CNPGC), known as Sinopharm, is a state-owned Chi\u00adnese com\u00adpany. In 2015, Sinopharm had 104,464 employ\u00adees and annual sales of over $44 bil\u00adlion. It is also ranked 205th<\/sup> on the Global For\u00adtune 500 list.<\/p>\n","protected":false},"excerpt":{"rendered":"

The Chi\u00adnese phar\u00adma\u00adceu\u00adti\u00adcal com\u00adpany Changchun Jienuo Med\u00adical Tech\u00adnol\u00adogy (CJMT), a sub\u00adsidiary of the Chi\u00adnese state-owned Sinopharm Group (www.sinopharm.com\/en), has acquired an exclu\u00adsive licence for the cer\u00advi\u00adcal can\u00adcer screen\u00ading test Gyn\u00adTect for China, Hong Kong and Macao from the Jena-based com\u00adpany oncg\u00adnos\u00adtics (www.oncgnostics.com). A four-mile\u00ad\u00ads\u00adtone agree\u00adment out\u00adlines how to obtain China Food and Drug Admin\u00adis\u00adtra\u00adtion (CFDA) [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[146],"tags":[],"class_list":["post-11422","post","type-post","status-publish","format-standard","hentry","category-2017-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=11422"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11422\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=11422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=11422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=11422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}